RE:RE:PwC sees continuation of US$ 5 to 15 Billion Bio M&A DealsAll this says that Big Pharma is facing a looming US$236 Billion patent cliff and are looking to address this issue with a multitude of M&A deals that will fall within Big Pharma's "sweet-spot" of between USD$ 5 Billion to USD$ 15 Billion according to the global consulting company PwC.
Given the deals that have been recently announced, Big Pharma has first started consummating deals at the lower end of the USD$5 to $15 Billion range and will then likely move up on the range to around USD$10 to $15 Billion over the next few months.